doi: DOI: 10.1186/s40880-016-0155-6

Treatment implications of posterior fossa ependymoma subgroups

Vijay Ramaswamy and Michael D. Taylor

Division of Haematology/Oncology, Hospital for Sick Children

[Abstract] Posterior fossa ependymoma comprises two distinct molecular entities, ependymoma_posterior fossa A (EPN_PFA) and ependymoma_posterior fossa B (EPN_PFB), with differentiable gene expression profiles. As yet, the response of the two entities to treatment is unclear. To determine the relationship between the two molecular subgroups of posterior fossa ependymoma and treatment, we studied a cohort of 820 patients with molecularly profiled, clinically annotated posterior fossa ependymomas. We found that the strongest predictor of poor outcome in patients with posterior fossa ependymoma across the entire age spectrum was molecular subgroup EPN_PFA, which was recently reported in the paper entitled “Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis” in the Journal of Clinical Oncology. Patients with incompletely resected EPN_PFA tumors had a very poor outcome despite receiving adjuvant radiation therapy, whereas a substantial proportion of patients with EPN_PFB tumors can be cured with surgery alone.

Chinese Journal of Cancer 2016, Volume: 35, Issue 11

[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)
[Google Scholar]

Cite this article

Vijay Ramaswamy and Michael D. Taylor. Treatment implications of posterior fossa ependymoma subgroups. Chin J Cancer. 2016, 35:93. doi:DOI: 10.1186/s40880-016-0155-6


Export citations

EndNote